Lucigen ClearColi - E. coli that lacks LPS

Instead of removing lipopolysaccharide (LPS) contamination from your protein or plasmid DNA preparations, eliminate the LPS at the source. Genetically modified LPS from a novel E. coli strain produces functionally clean recombinant proteins and plasmids. ClearColi™ BL21(DE3) cells are the first commercially available competent cells with a modified LPS (Lipid IV_A - see Fig. 1) that does not trigger the endotoxic response in mammalian cells. ClearColi™ cells lack outer membrane agonists for hTLR4/MD-2 activation; therefore, activation of hTLR4/MD-2 signalling by ClearColi™ is several orders of magnitude lower compared with E. coli wild-type cells, and heterologous proteins prepared from ClearColi™ are virtually free of endotoxic activity. After minimal purification from ClearColi cells, proteins or plasmids, which may still contain Lipid IV_A, can still be used in most applications without eliciting an endotoxic response